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Background: Initial symptoms of amyotrophic lateral sclerosis (ALS) are often subtle and can delay diagnosis. This
exploratory analysis was conducted to better characterize the pre-diagnosis pathway undertaken by patients with
ALS in the US Centers for Medicare & Medicaid Services Medicare longitudinal claims database.
Methods: Quarterly Medicare claims data were analyzed to determine the pre-diagnosis pathway for an ALS patient
cohort that included patients aged ≥ 65 years with ≥ 2 ALS claims (International Classification of Diseases, Ninth Revi-
sion, Clinical Modification code 335.20) between the first quarter of 2007 and the fourth quarter of 2009, and were en-
rolled in Medicare ≥ 2 years before the first ALS claim (diagnosis). A cohort of Medicare patients without claims for
motor neuron diseases were identified for comparison. A subset of these patients with ≥ 3 years of claims data was in-
cluded in a time to diagnosis analysis. Data extraction included the most common initial symptoms of ALS, the time
from first ALS symptom to diagnosis, and the diagnostic procedures performed before the diagnosis of ALS.
Results: A total of 399 patients met the inclusion criteria and were included in the ALS cohort; 272 patients were
included in the time to diagnosis cohort. Before the quarter of diagnosis, symptoms that were more frequently seen in
the ALS cohort than the general Medicare cohort included muscle weakness, lack of coordination and speech/
swallowing difficulties. Limb-onset ALS (74%) was more common than bulbar-onset ALS (17%). Median time to diagno-
sis for limb- and bulbar-onset patients was 2.5 years and 1.25 years, respectively. The most common tests conducted
before the quarter of diagnosis included sensory and motor nerve conduction tests, imaging studies, and electromyog-
raphy; however, a substantial number of patients did not receive any nerve conduction testing. Motor nerve conduc-
tion testing in patients with bulbar-onset ALS had the largest impact on time to diagnosis.
Conclusions: This analysis describes a diagnostic delay for patients with ALS in the US Medicare population, similar to
previous reports. The development of tools and ongoing education that can help to identify patients with ALS earlier in
their disease course is needed.
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Amyotrophic lateral sclerosis (ALS) is a progressive neu-
rodegenerative disease affecting the upper and lower
motor neurons [1]. ALS is fatal; death generally occurs
within 2 years after symptom onset although up to 10%
of patients with ALS survive more than 10 years [2].
Prognostic factors have been identified for ALS: 1)
advanced age is associated with increased incidence of* Correspondence: james.williams@biogenidec.com
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reproduction in any medium, provided the orALS; 2) women have a shorter survival time than men;
and 3) bulbar-onset ALS is associated with shorter sur-
vival [2]. Currently, there is no cure for ALS and treat-
ment is largely supportive. Riluzole is the only drug
approved by the US Food and Drug Administration for
the pharmacologic treatment of ALS; however, the effect
of riluzole on survival is modest [3].
The initial symptoms of ALS are often subtle (limb or
shoulder weakness, difficulty walking) despite the deadly
nature of the disease [1]. Unrecognized symptoms
can result in delays in the diagnosis of ALS as well asl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a delay from symptom onset to diagnosis that has
remained unchanged for more than a decade and ranges
from 8.0 to 15.6 months [4]. Diagnostic delay may deter
timely beneficial intervention, heighten psychological
distress, prevent clinical trial participation, and add to fi-
nancial and social support issues [5]. In addition, delays
in diagnosis also may prevent timely referral to centers
offering a multidisciplinary approach to ALS care, which
has been shown to prolong survival [6,7]. Patients re-
ceiving care from a multidisciplinary team also have re-
ported a higher quality of life [8]. Misdiagnosis has been
reported to result in unnecessary interventions, such as
surgery [9-11]. Attempts to improve the diagnostic delay
in ALS have identified reasons for the delay including
atypical symptoms of ALS, referrals to other depart-
ments before referral to a neurologist, and a lack of
recognition of symptoms of the ALS in the general prac-
titioner office [12].
This exploratory analysis was undertaken to investigate
the initial symptoms and time to diagnosis for patients
with ALS in the US Centers for Medicare & Medicaid
Services (CMS) longitudinal claims dataset. Key diagnos-
tic tests prior to the quarter of diagnosis also were ex-
amined. This was a pilot analysis for a broader project
meant to identify “Red Flag” signs and symptoms that
could be used to encourage expedited referrals in pa-
tients with early ALS symptoms.Methods
Data source
This retrospective study used data from the CMS longi-
tudinal claims dataset (http://www.resdac.org). In the
United States, Medicare provides coverage to those aged
65 years and older and offers coverage for those who are
younger than 65 years with a disability, such as patients
with ALS [13]. The Medicare dataset used in this study is
made available by the US Department of Health and
Human Services as a way to improve transparency and
provide a source of information that can be used to im-
prove health care [14]. Included in the dataset were adju-
dicated claims data for approximately 80% of Medicare
recipients covered by traditional fee-for-service plans (i.e.,
patients with Medicare Advantage plans were not in-
cluded); the data set is maintained by the CMS. All (100%)
patient institutional claims between the first quarter (Q1)
of 2005 and the fourth quarter (Q4) of 2009 were included
in the dataset. In addition, physician office data were avail-
able for 5% of patients in the database. These patients
were identified for inclusion in the 5% physician office
sample using the last 2 digits of their Medicare account
number. Once included, beneficiaries remain in the phys-
ician office sample from enrollment until death. In thepublic datasets, data were classified only by quarter of ser-
vice; dates of service were not available.
Study cohort descriptions
Claims data from Q1 2005 to Q4 2009 were reviewed to
identify patients who met the study inclusion criteria.
Patients were included in the ALS cohort if the follow-
ing criteria were met: patients had to be aged 65 years
or older, had a first ALS claim (International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification
[ICD-9-CM] code 335.20) and two or more ALS claims
(ICD-9-CM code 335.20) from Q1 2007 to Q4 2009, and
were in the CMS dataset for 2 years or more before the
first ALS claim, with available physician office data. To
ensure there was a minimum of 3 years of prior claims
to examine for ALS symptoms present prior to diagno-
sis, the time to diagnosis analysis was based on a cohort
of 272 patients with an initial ALS claim between Q1
2008 and Q4 2009. In addition, data from the general
Medicare population (Q1 2008 to Q4 2009) formed a
Medicare cohort for comparison.
Study design
Adjudicated inpatient, outpatient, and physician office
CMS Medicare claims were reviewed for this analysis.
Data extraction included the most common initial symp-
toms of ALS, time from first ALS symptom to diagnosis,
and diagnostic procedures performed before the diagno-
sis of ALS. Symptom, procedure, and diagnostic codes
were evaluated in patients in the ALS cohort; symptom
and diagnostic codes were evaluated in the Medicare
cohort.
Symptoms of ALS were classified based on the likeli-
hood that they were related to a patient’s disease. A
multi-step process was used to develop a classification
of likelihood (high or moderate) that the symptoms re-
ported in the medical claim were ALS related. Following
an initial review of available literature, a patient record
analysis was performed on the complete claims history
of 50 Medicare patients with a diagnosis of ALS to
review the frequency of reported symptoms before diag-
nosis. Based on this analysis, an initial list of possible
ALS-related symptoms was generated and reviewed by
one of the authors (DK) who has significant clinical ex-
perience in the diagnosis and treatment of ALS. Symp-
toms on the list were then further classified as high or
moderate likelihood symptoms and were used to deter-
mine a patient’s initial ALS symptom (Table 1).
Symptoms defined in this study as “high likelihood” in-
cluded symptoms that were highly associated with ALS
based on a literature review of ALS symptomatology,
frequency in the 50-patient Medicare cohort, and con-
firmation by the ALS specialist. Because of the close as-
sociation, a code for a single high likelihood symptom
Table 1 Codes identified as high or moderate likelihood
of being first ALS symptom
Priority Subgroup Diagnosis of interest
ICD-9-CM
codes


























Gait Difficulty walking 719.7
Gait abnormality 781.2










Moderate Pain Pain in joint 719.4
Pain in limb 729.5
Other Disorder of muscle
and/or ligament
728.X
ALS, amyotrophic lateral sclerosis; ICD-9-CM, International Classification of
Diseases, Ninth Revision, Clinical Modification.
Beneficiaries in 5% Medicare sample
Q1 2007 to Q4 2009
(N = 2,051,066)
Aged ≥ 65 years
(n = 1,634,708)
≥ 1 ALS claim* from Q1 2007 to Q4 2009
(n = 1570)
≥ 2 ALS claims* from Q1 2007 to Q4 2009
(n = 1149)
In data set ≥ 2 years before first claim
(n = 399)
First ALS claim* from Q1 2008 to Q4 2009
(n = 272)†
Figure 1 Amyotrophic lateral sclerosis (ALS) cohort eligibility.
*International Classification of Diseases, Ninth Revision, Clinical
Modification code 335.20. †Population for time to diagnosis
evaluation. Q1, quarter one; Q4, quarter four.
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Symptoms defined as “moderate likelihood” included
those associated with ALS based on frequency in the 50-
patient Medicare cohort and confirmed by the ALS spe-
cialist. Coding for two moderate likelihood symptoms in
a single quarter was required to define the first ALS
symptoms. The first instance of either a single high like-
lihood symptom or two moderate likelihood symptoms
was used to define the quarter of first ALS symptom.
Symptoms were further grouped into bulbar, limb, nerve,
respiratory, and other symptom categories to reflect the
common symptom classes present in ALS.
The prevalence of diagnostic codes present in medical
claims 2 years prior to the first ALS claim was tabulated.
Multiple diagnostic codes related to a single sign or
symptom were grouped together. A prevalence rate ratio
was calculated for identified symptom or diagnostic
codes by dividing the percentage of patients in the ALScohort having a given symptom by the percentage of pa-
tients in the Medicare cohort with the same symptom.
Data for the signs and symptoms with a prevalence of at
least 10% in the ALS cohort or with a prevalence ratio
of at least 5 were identified. Data also were reviewed to
identify a time from first symptom(s) to diagnosis of
ALS and the frequency of use of common diagnostic
procedures. The analyses were exploratory in nature. No
hypothesis testing was conducted.
Results
The Medicare 5% sample housed information for just
over 2 million patients with physician office data during
the study period. A total of 399 patients (53% female) in
the database met the inclusion criteria (Figure 1). The
percentage of females (55%) in the Medicare 5% sample
over the timeframe of interest (2005–2009) also was
slightly higher than males. Within our defined ALS co-
hort, 272 qualified for the evaluation of time to diagnosis
based on their first ALS claim occurring between Q1
2008 and Q4 2009.
In the time to diagnosis cohort, limb-onset ALS (74%)
was more common than bulbar-onset ALS (17%); evi-
dence of both limb and bulbar symptoms occurring con-
currently at onset was noted in 8% of patients. Median
time to diagnosis from first high and/or moderate likeli-
hood limb or bulbar symptom in the 272 patient cohort
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shorter for patients with bulbar-onset than for patients
with limb-onset (1.25 years vs 2.5 years, respectively),
and, in the subgroup where limb and bulbar symptoms
appeared at the same time, the median time to diagnosis
was only 0.25 years. In the bulbar-onset subgroup, 38%
of patients were diagnosed with ALS within three quar-
ters of their first bulbar symptom,; whereas only 21% of
patients with limb-onset disease were diagnosed within
three quarters of their first symptom.
Although a broad range of symptoms was included for
review in this analysis, the cardinal symptoms of muscle
weakness and speech difficulties (speech disturbances
and voice resonance disorder) were more frequently re-
ported in the ALS cohort in the eight quarters before
diagnosis compared with the Medicare cohort (Table 2).Table 2 Symptoms/diagnoses observed at a frequency > 10%
Symptom group Symptom/diagnosis P
Bulbar Speech disturbance 24
Bulbar Voice resonance disorder 15
Limb Muscle weakness (generalized) 30
Limb Lack of coordination 13
Bulbar Dysphagia§ 27
Nerve Hereditary and idiopathic peripheral neuropathies§ 35
Nerve Cervicalgia 18
Limb Gait abnormality/difficulty walking 32
Other Transient cerebral ischemia 13
Other Loss of weight 17
Other Stroke 11
Other Lumbago/backache§ 52
Other Malaise and fatigue 56
Other Syncope and collapse 26
Limb Pain in limb 44
Other Esophageal reflux 31
Other Constipation 15
Respiratory Pulmonary collapse/failure 17
Other Dizziness and giddiness 12
Other Swelling in limb 11
Respiratory Respiratory difficulties§ 62
Other Hypothyroidism 27
Other Nausea, vomiting, etc. 11
Limb Pain in joint 31
Respiratory Bronchitis 18
Respiratory Chronic airway obstruction 19
Respiratory Acute upper respiratory infection 12
ALS, amyotrophic lateral sclerosis.
*Frequency > 10% in the eight quarters before diagnosis of ALS (not including the q
†Prevalence in the Medicare cohort.
‡Percentage of patients in the ALS cohort having a given symptom/the percentage
§Includes multiple symptom types.In addition, a select number of diagnoses present in less
than 10% of the ALS cohort were observed at a substan-
tially higher rate than in the Medicare cohort (Table 3).
The presence of myopathy, cervical/thoracic or lumbar
spondylosis with myelopathy, or muscular disuse atrophy
was associated with a longer median time to diagnosis of
ALS from the onset of the first limb or bulbar symptom
compared with that determined for the entire cohort.
This increased time was particularly marked for patients
given a diagnosis of spondylosis with myelopathy.
Further analysis of selected cardinal limb and bulbar
symptoms identified that, for each of these symptoms,
there was a proportion of patients who presented eight
quarters or more before being diagnosed with ALS, par-
ticularly patients with gait abnormalities or difficulty
walking (27% and 33%, respectively; Table 4). The morein the ALS cohort* compared with the Medicare cohort†





























of patients in the Medicare cohort with the same symptom.









Median time to diagnosis from
first limb/bulbar symptom, years‖
Nerve Chronic inflammatory
demyelinating polyneuropathy
2 < 1 30.5 ND
Nerve Myopathy (including
myopathy with weakness)
8 < 1 28.6 2.75
Nerve Unspecified disease of spinal cord
(including myelopathy NOS)
5 < 1 19.6 2.25
Nerve Cervical/thoracic or lumbar
spondylosis with myelopathy
6 1 11.2 3.50
Limb Atrophy, muscular disuse 5 1 5.0 2.75
ALS, amyotrophic lateral sclerosis; ND, not determined because of small sample of patients with chronic inflammatory demyelinating polyneuropathy in
the time to diagnosis cohort; NOS, not otherwise specified.
*Observed at a frequency < 10% with a prevalence ratio ≥ 5 compared with the Medicare cohort.
†In the eight quarters before ALS diagnosis, not including the quarter of diagnosis (n = 399).
‡Prevalence in the Medicare cohort.
§Percentage of patients in the ALS cohort having a given symptom/ the percentage of patients in the Medicare cohort with the same symptom.
‖In the time to diagnosis cohort (n = 272).
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in the vast majority of patients that received their first
diagnosis of speech disturbance, voice resonance dis-
order, or dysphagia 0 to three quarters before ALS was
diagnosed.
The most common diagnostic tests employed in the
eight quarters before diagnosis (not including the quar-
ter of diagnosis) included sensory and motor nerve con-
duction tests, magnetic resonance imaging (MRI) and
computed tomography scans, and electromyography of
limbs, abdomen, or spine (Table 5). With the exception
of exams of the throat and/or upper gastrointestinal
tract, these tests were conducted in a higher proportion
of the patients with limb-onset subgroup compared with
the bulbar-onset subgroup. In the limb-onset subgroup,
time to diagnosis was similar in patients with nerve con-
duction testing, imaging or electromyography (Table 5).
In the bulbar-onset subgroup, patients who underwentTable 4 Average, median, and distribution by quarter of onse
ALS cohort
Symptom group Symptom Average, quarters Med
Limb Muscle weakness 2.64
Gait abnormality 4.53
Difficulty in walking 5.18
Lack of coordination 3.26
Bulbar Speech disturbance 1.83
Voice resonance disorder 3.00
Dysphagia 1.07
ALS, amyotrophic lateral sclerosis.an MRI of the neck and spine without dye had a longer
time to diagnosis compared to the entire bulbar-
onset subgroup (2.5 years and 1.25 years, respectively),
whereas an MRI of the brain with or without dye was as-
sociated with a shorter time to diagnosis (0.25 years). A
positive benefit on time to diagnosis was also measured
for the utilization of motor nerve conduction tests in
patients with bulbar-onset disease (0.25 years and 0.5
years compared with 1.25 years for the entire bulbar-
onset subgroup); sensory nerve conduction tests were
associated with a longer time to diagnosis (2.5 years).
Discussion
Claims for patients in the ALS cohort during the pre-
diagnosis period encompassed a wide range of symp-
toms. The most frequent symptoms before diagnosis in
patients in the ALS cohort were respiratory difficulties,
malaise and fatigue, and lumbago/backache. While othert relative to ALS diagnosis for selected symptoms in the
Distribution of patients by time from
symptom onset to ALS diagnosis (in quarters)
ian, quarters 0–3, % 4–7, % 8–11, % 12+, %
1.0 75 12 7 5
2.0 61 12 12 15
3.0 52 15 21 12
1.0 68 16 9 7
1.0 89 7 3 1
2.0 76 8 11 5
1.0 95 5 0 0
Table 5 Diagnostic testing frequency and median time to diagnosis














Sensory nerve conduction test 38 2.75 41 2.75 30 2.50
Motor nerve conduction
test with F-wave
26 2.75 30 2.75 18 0.25
Motor nerve conduction
test without F-wave
23 2.75 24 2.88 18 0.50
Imaging studies
MRI of neck and spine without dye 25 2.50 29 2.75 15 2.50
CT scans (head or brain) with/without
contrast material
39 2.50 43 2.75 19 1.25
MRI of brain with/without dye 28 2.75 29 2.75 28 0.25
Electromyography
Limb electromyography (2 extremities
and related paraspinal areas)
19 2.75 22 2.50 12 ND
Limb electromyography (1 extremity
and related paraspinal areas)
16 2.50 18 2.75 10 ND
Other
Exam of throat and/or upper
gastrointestinal tract
22 2.50 15 3.00 48 2.50
ALS, amyotrophic lateral sclerosis; CT, computed tomography; MRI, magnetic resonance imaging, ND, not determined, frequency of testing < 15%.
*n = 399.
†In the eight quarters before ALS diagnosis, not including the quarter of diagnosis.
‡In the time to diagnosis cohort (n = 272).
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sues, muscle weakness) occurred less frequently, rates
were substantially higher in patients in the ALS cohort
compared with those in the Medicare cohort. It is pos-
sible that increased physician awareness of these non-
cardinal symptoms, in conjunction with more widely
known classical symptoms of ALS such as dysphagia,
could drive the referral of pre-diagnosis patients and/or
earlier diagnosis of ALS.
Limb- and bulbar-onset ALS occurred at rates relative to
one another that are consistent with those in published
literature [4]. In this analysis, patients with bulbar-onset
disease were diagnosed more quickly than those with limb-
onset disease. Turner et al. [15] also found that diagnostic
latency was shorter for patients with bulbar symptoms than
those with lower limb symptoms.
Consistent with data from other populations, a delay
in the diagnosis of ALS in the US Medicare population
was observed [4,12]. For cardinal limb-onset symptoms
such as gait abnormality and difficulty walking, a high
proportion of patients exhibited these symptoms at least
eight quarters before being diagnosed with ALS. The
early presence of these symptoms highlights the import-
ance of educating neurologists on these initial clinical
signs and symptoms of ALS to minimize diagnostic
delays. Interestingly, specific conditions (myopathy, cer-vical/thoracic or lumbar spondylosis with myelopathy,
muscular disuse atrophy) that were relatively uncommon
in the ALS population studied, but still more prevalent
than in the general Medicare population, were associated
with a longer time to diagnosis of ALS. This finding sug-
gests that “incorrect” diagnoses, particularly spondylosis
with myelopathy, may further delay the formal diagnosis
of ALS.
The use of recommended diagnostic testing was less
than would be expected given current clinical guidelines
for the diagnosis of ALS [16]. The Awaji criteria recom-
mend the incorporation of electrophysiologic data along
with the assessment of clinical status [17]. In the current
analysis, sensory and motor nerve conductions tests
were the most frequent diagnostic tests performed be-
fore the quarter of diagnosis of ALS.
Overall, the median delay in time to diagnosis was con-
sistent across testing modalities in limb-onset ALS. This
highlights the difficulty of making the diagnosis even
when recommended testing is conducted. In patients
with bulbar-onset ALS, test selection influenced time to
diagnosis. In this group, a positive benefit was observed
for motor nerve tests, whereas sensory nerve tests were
associated with a longer time to diagnosis. Specific elec-
tromyographic tests were found to be used in a minority
of patients prior to the quarter of diagnosis of ALS, and
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to diagnosis in the limb-onset subgroup. In a systematic
review, the incorporation of electrophysiologic testing in-
creased the number of patients identified as having prob-
able or possible ALS [17]. However, in the context of
these results, the impact of neurophysiologic testing on
time to diagnosis should be further explored.
Several limitations of this study should be noted. First,
the list used for symptom identification was reviewed by
only one ALS expert; use of a panel could have gener-
ated a different ranking for high and moderate likelihood
symptoms. Overall, limb symptoms were less specific
than bulbar symptoms. The longer time to diagnosis
might have been overestimated by limb symptoms that
represented unrelated medical comorbidity rather than
ALS. In addition, while the Medicare database offered a
large population for research purposes, it only included
those patients enrolled in Medicare and did not include
patients covered under commercial insurance. Medicare
insurance is generally available for US citizens after their
65th birthday. Although select patient groups under the
age of 65 years are eligible for Medicare (e.g., patients
with ALS, patients with Social Security disability benefi-
ciaries, patients with end stage renal disease), these
groups are not representative of the average patient
under the age of 65 years, and were therefore excluded
from the analysis. Moreover, the small sample size lim-
ited the strength of the analyses.
Conclusions
A diagnostic delay is evident in this analysis of the US
Medicare population. Overall, the results of this explora-
tory analysis support the need for additional education
and tools for health care providers to increase awareness
of the symptoms of ALS and promote prompt referral to
ALS specialists for expert diagnosis. Early recognition of
ALS symptoms is key to a more efficient referral and diag-
nostic process for patients with ALS. Additional studies
are needed to confirm the findings from this analysis.
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